In this study we have re-examined the molecular mechanisms involved in activation of T cells by dendritic cells (DC). Human peripheral blood DC (PBDC) were derived by 2 h adhesion followed by 7 day culture in a combination of granulocyte macrophage colony stimulating factor and IL-4, and depletion of residual T and B cells. These PBDC were used to induce autologous T cell proliferation in a CD3-dependent response, and antibodies against CD11a/18 and CD86 were used as control inhibitors of accessory function. Antibodies against five of the cell surface molecules that we have recently identified on the surface of DC, CD13, CD87, CD98, CD147 and CD148, and an antibody which recognizes a molecule that has not as yet been identified, all inhibited the CD3-induced T cell proliferation. These findings were observed not only when antibodies were present throughout the culture, but also when they were prepulsed on to the surface of the DC, suggesting the inhibition was mediated via the antigenpresenting cells rather than the T cell. The same set of antibodies also inhibited an allospecific mixed lymphocyte reaction, confirming that the inhibitory effect was not dependent on the use of a CD3 antibody as the stimulating agent. All the antibodies of known specificity inhibited both CD4 and CD8 T cells equally. Unlike CD87, CD98 and CD147 antibodies, which inhibited activation of both CD45RA (naive) T cells and CD45RO (memory) T cells, CD13 and CD148 appeared to be involved in activation of naive cells only. The molecules identified in this study have not previously been demonstrated to play a role as accessory molecules on DC, the cells that are pivotal for immune induction. Therefore they may provide new potential targets for modulation of the immune response at the APC level.
Introduction
DQ, Ia3, ascites, IgG2a mouse mAb, gift of Professor R.
ascites, IgG2a; BU89, ascites, IgG1; 2G12, IgM; and 4F2, IgG2a); CD147 [HIM6 and HI197, both purified ascites, IgG1 Winchester) and CD14 (HB246, IgG2b mouse supernatant mAb, gift of Professor P. C. L. Beverley) followed by anti-(26); H84, ascites, IgG2b]; CD148 (143-41, ascites, IgG1); CD164 (105A5, IgG3) and the unclassified WM78 (purified mouse Ig-coated immunomagnetic beads. This protocol also removed all HLA-DR-expressing (activated) macrophages culture supernatant, IgG1) and CNA42 (IgM). Second label antibody used was FITC-conjugated rabbit anti-mouse IgG and resulted in a T cell population that was Ͼ80% CD3 ϩ , with a mean fluorescence intensity in the region of 100. This (Dako, Glostrup, Denmark). phenotype was confirmed using mAb against CD14, HLA-DR Immunofluorescent flow cytometry and HLA-DQ, and later with mAb against CD13 and CD87 (see below), and all showed Ͻ5% positive cells, with negligible Both DC and T cells were incubated on ice in HBSS with 10% normal rabbit serum (NRS) (Gibco) for 15 min to prevent nonmean fluorescence. To separate T cell subsets, these T cells were incubated with CD8 (UCH-T4, IgG2a mouse supernatant specific binding. Primary mAb was then added to the cells at a titre of 1:500 (unless otherwise shown) without premAb, gift of Professor P. C. L. Beverley) when CD4 ϩ T cells were required, with CD4 (Q4120, IgG1 mouse supernatant washing and incubated for 45 min on ice. Cells were washed 3 times in HBSS/10% NRS. Fluoresceinated mAb (rabbit antimAb, gift of Dr Q. Sattentau) when CD8 ϩ T cells were required, with CD45RO (UCH-L1, IgG2a mouse supernatant mAb, gift mouse IgG) was added (diluted 1:20 in HBSS/10% NRS) and cells incubated for 45 min on ice. Cells were washed 3 times of Professor P. C. L. Beverley) for CD45RA ϩ T cells and CD45RA (SN130, IgG1 mouse supernatant mAb, gift of Proin HBSS/10% NRS, fixed overnight in 3.7% formaldehyde/ PBS, and data acquired on a Becton Dickinson FACScan and fessor P. C. L. Beverley) for CD45RO ϩ T cells. CD4 ϩ T cells were found to be 82% pure (as judged by staining with analysed using WinMDI software. For each sample not less than 5000 events were acquired. The data was examined QS4120) and CD8 ϩ T cells were found to be 75% pure (as judged by staining with UCH-T4) (data not shown). CD45RA ϩ relative to a negative control sample with no primary mAb where the percentage positive cells was always Ͻ5%. The T cells were found to be 95% pure (as judged by staining with SN130) and CD45RO ϩ T cells were found to be 97%
FACScan was calibrated using Quantum 26 microbeads (Flow Cytometry Standards, San Juan, Puerto Rico). DC or T cells pure (as judged by staining with UCH-L1) (data not shown). T cells were frozen at -80°C in 90% FCS/10% DMSO during were gated via forward and side scatter so as not to include any cell debris for analysis. All analyses were carried out on the DC culture period prior to assay.
Cell viability was monitored using both Trypan blue exclua minimum of three different individuals. sion and a MTT assay. For the latter assay, briefly, a 5 mg/ml Proliferation assays MTT stock solution was prepared in PBS and stored at 4°C (always for Ͻ2 weeks). Then 10 µg MTT (in 20 µl volume/ DC (irradiated, 3000 rad) were incubated at 37°C/5% CO 2 with autologous T cells, and with test mAb where noted, for well) was added to each test cell population in a 96-well ELISA plate and the plates incubated at 37°C for 4 h. Then 2 h in flat-bottom 96 well plates (Nunc, Roskilde, Denmark). CD3 (Harlan-Sera, Loughborough, UK) was added at to give 100 µl of 10% SDS-0.01 M HCl was added and the plates were read on an ELISA reader at an optical density of 570-a final volume of 200 µl. After the initial titrations, 3ϫ10 4 DC, 10 5 T cells and 0.1 µg/ml CD3 mAb were used in all subsequent 630 nm. The test populations consisted of both DC and T cells separately, as well as DC but with mAb present during the experiments. The DC-T cell-CD3 cultures were incubated for 48 h and pulsed with 1 mCi [ 3 H]thymidine (ICN Biomedical, 4 h period, and both DC and T cells that been pre-pulsed with mAb and then washed 3 times in RPMI to remove any High Wycombe, UK) for 16 h. Cells were harvested and proliferation measured by liquid scintillation counting. All remaining mAb (as outlined below). assays were performed in triplicate. Inhibition is expressed mAb as a percentage of thymidine incorporation of triplicates with no test mAb. Apart from the mAb listed above, many of the mAb used to characterize the phenotype of DC and T cells were obtained For prepulse assays, DC were incubated with test mAb for 1 h at 37°C/5% CO 2 , then washed 3 times in RPMI before initially from the Sixth Human Leukocyte Differentiation Antigen Workshop, and subsequently from the originators. Those used addition of T cells and CD3 as before. To fix the DC, cells were treated with 0.05% glutaraldehyde for 30 s at room in this study were against CD11a (CD11a-5E6, IgG1; CD11a-6B7, IgG1); CDw12 (M67, IgG1); CD13 (MCS-2, ascites, temperature and the fixative quenched with 0.2M lysine (pH 7) for 3 min at room temperature. PBDC were isolated, incubated with a panel of mAb, and examined using the FACScan as outlined in Methods. The data were analysed using WinMDI software. All experiments were performed on at least three individuals and 5000 events recorded. The results of a representative experiment are shown (shaded areas) including not only the names of the molecules against which the mAb used are targeted, but also the particular mAb(s) used in the study. These profiles are relative to the controls (no primary mAb used, unshaded). MFI of the shaded profiles are recorded.
subsequent incubation and assay conditions were the same also noted to express CD13, CD87, CD98, CD147 and CD148, and to bind one mAb (WM78) which recognizes a molecule as those for the DC-T cell-CD3 assays.
that has not yet been assigned CD nomenclature. T cells, known to be positive for CD3 and negative for CD14, HLAResults DR, HLA-DQ, CD13 and CD87, showed variable levels of detectable CD98 depending on which mAb was used. For DC and T cell phenotype example, one mAb, J1-G3B/AHN-18.1, bound to 100% of The phenotype of the PBDC is illustrated in Fig. 1 . As has cells, with an MFI in a representative experiment of 370, been reported previously, PBDC were negative for CD3 and whereas although the J3-E1B/AHN-18 mAb bound to Ͼ90% CD19. A small percentage (14%) were weakly positive for of the same T cells the MFI was only 24 (compared to 612 CD14, which is consistent with other studies where it is only on PBDC in the same experiment). The other three CD98 the most 'activated' DC populations that have no CD14 ϩ cells mAb that showed binding on a proportion of T cells (MEM108, present at all. These cells were Ͼ95% positive (range 94-CAF7 and BU53) all showed mean fluorescence of Ͻ20, i.e. 100%, over five individuals) with a high mean fluorescence 10-fold less than that seen on PBDC. CD147 was expressed intensity (MFI) (range 4537-5789) for HLA-DR and Ͼ80%
on a high percentage of T cells (75-95%), but the MFI (e.g. positive (range 76-88%) with a lower range of MFI (143-490) maximum 35 in a representative experiment) was much lower for HLA-DQ. PBDC also expressed CD1a (70-95%, MFI 989-than that seen on PBDC. The levels of CD148 expression 1887), CD18 (95-100%, MFI 2356-5187), and CD86 (67-were also much lower on T cells (e.g. MFI of 8, compared to 96%, MFI 249-604). These findings are in accordance with 127 on PBDC) and only 10-15% of the cells expressed this molecule. the established PBDC phenotype. In addition, PBDC were
DC-induced autologous T cell co-stimulation assay
The first part of the study aimed to establish a reliable autologous assay of DC co-stimulatory function. The approach selected was based upon previous related similar studies (23) (24) (25) . The experiments were performed using soluble CD3, rather than CD3 mAb coated to the culture well, in order that the TCR signal be delivered to the T cell in the context of a direct physical interaction with the PBDC, which could be monitored visually using the formation of clusters around the DC. Thus in this assay the CD3 mAb provides the first signal and the second signal comes from the DC. By morphology, the clustering was striking, whereas in the absence of CD3 mAb only small clusters were observed and in the absence of PBDC no clusters were observed (data not shown).
To confirm the co-stimulation dependence of the assay further, the different components were titrated into the assay, and the outcome monitored using tritiated (Fig. 2c) showed that 0.1 µg/ml CD3 and 10 5 T cells could be used, and that these levels gave sub-maximal responses, thus allowing for both positive and negative effects to be observed.
In order to confirm that the T cell activation in this assay was dependent on delivery of classical adhesive-co-stimulatory signals from the DC, the effects of mAb directed at CD11a and CD18 were used. The results of a representative experiment are shown in Fig. 3 . In all cases Ͼ80% inhibition of proliferation by these mAb was observed and the results were statistically significant (Welch two-tailed t-test P Ͻ 0.05). In similar experiments CD80 gave~50% inhibition, CD86 mAb gave between 32 and42% inhibition, and when the two mAb were added together mean inhibition was 60%, with similar mAb against CD13 (7H5), CD98 (J3-E1B/AHN-18), CD147 (H84) and CD148 (143-41) are all inhibitory; and that, furthermore, the level of inhibition is dependent upon the concentration of mAb used. The CD30 mAb (11D1-H10) had no effect. All three CD13 mAb gave similar inhibition (Ͼ40% in each of response, but there was some variability in the degree of three experiments). Two of the three CD147 mAb tested inhibition depending upon which mAb was used. Figure 5 (a) inhibited the response (HIM6 and H84) but the third mAb shows a representative experiment. These differences in (HI197) (data not shown) did not. The CD148 mAb (143- 41) percentage inhibition were reproducible, and statistically sigalso gave a consistent pattern of inhibition and likewise nificant compared to the test assays (P Ͻ 0.05). For example, WM-78, a mAb to a molecule not yet assigned a CD number, HD-uPA-R15.4.1 was consistently the most potent inhibitor showed percentage inhibition in a similar range (data not (percentage inhibition range 72-91% in three experiments) shown).
and this was seen even at a dilution of 1:1000 (data not shown). The mAb IIIF10 (range 34-67%) and IID7 (range 41-In these experiments, all mAb to CD87 inhibited the Fig. 3 . Inhibition of T cell proliferation by CD11a and CD18 mAb. In total, 3ϫ10 4 irradiated PBDC, 10 5 autologous T cells and 0.1 µg/ml CD3 were incubated for 48 h and pulsed with [ 3 H]thymidine for 16 h. The mAb against CD11a (CD11a-5E4, 2.8 µg/ml; CD11a-6B7 and AZN-L27, 0.3 µg/ml) and CD18 (AZN-L18, 0.3 µg/ml) were added at 1:500 dilution as indicated. Control mAb (data not shown) were against CDw12, CD30, CD33 and CD164. Results are shown as mean Ϯ SD of triplicate wells and data is from a representative experiment. 59%) were also inhibitory at 1:100 dilution, despite almost no detectable binding to the PBDC surface by FACS analysis. One CD87 mAb (VIM5) did not inhibit the response (data not shown). These differences were not due to variability in mAb concentration, which ranged from 0.025 to 1.5 µg/ml. Figure 5 (b) shows a similar experiment with CD98 mAb. Again the results were all statistically significant compared to controls. The mAb J1-G3B/AHN-18.1 (1.5 µg/ml), J3-E1B/ AHN18 (3.2 µg/ml), BK19.9 and CAF7 (0.8 µg/ml) were consistently inhibitory. For example, addition of J1-G3B/AHN-18.1 resulted in a percentage inhibition range from 97 to 99% inhibition in three experiments when used at 1:500 dilution; the other inhibitory mAb gave 50-80% inhibition at this dilution. may therefore have an effect on T-T interactions as well as on DC-T cell interaction, the same panel of mAb were also tested at the same concentrations, but using PMA and
Effect of prepulse mAb on autologous DC-induced T cell
ionomycin instead of DC and CD3 as the activating signal. In proliferation two consecutive assays neither CD13 nor CD87 had an inhibitory effect. In contrast, the results for CD98 mAb were In order to ascertain whether the effects observed by these similar to those seen in the other activation assays, i.e. mAb were mediated via binding to the PBDC, PBDC were maximum (Ͼ90%) inhibition was seen with both J1-G3B/ pulsed with mAb of interest for 1 h at 37°C, before being AHN18.1 and J3-E1B/AHN18. Four other CD98 mAb tested washed 3 times in RPMI to remove any unbound mAb.
(BK19.9, BU53, BU89 and 4F2) showed significant inhibition Aliquots both of pulsed PBDC and of control T cells were but only between 20 and 30%. Likewise, CD147 (H84) and examined by Trypan blue exclusion and in the MTT assay, CD148 (143-41) mAb showed Ͼ90 and 50% inhibition and there was no difference in cell viability indicating that the respectively. effects seen were not due to cytotoxicity. T cells and CD3 were added into the assay as outlined previously. The results CD4 ϩ T cell and CD8 ϩ T cell subsets are shown in Fig. 6 , and resemble those of the previous assay In order to assess whether mAb preferentially inhibited CD4 ϩ closely, again with the CD87 mAb HD-uPA-R15.4.1 and the T cells or CD8 ϩ T cells, responder T cell populations were CD98 mAb J1-G3B/AHN18.1 being the most striking inhibitors enriched for these phenotypes before the assay. Figure 7 for each respective specificity. Inhibition ranged from 62 to shows percentage inhibition of proliferation using either CD4 73% over three experiments for HD-uPA-R15.4.1 (pulsing or CD8 T cell subsets. All mAb tested inhibited both CD4 ϩ concentration 1:100) and from 97 to 99% over three experiand CD8 ϩ T cells. The mAb WM-78 inhibited CD4 ϩ T cell ments for J1-G3B/AHN18.1 (pulsing concentration 1:500).
proliferation by 43-48%, but CD8 ϩ T cells by only 10-15% in Where the PBDC were fixed after the prepulsing step, the two consecutive experiments (P Ͻ 0.0003); otherwise there CD98 (J1-G3B/AHN18.1) inhibition remained Ͼ90%. For were no significant differences between the inhibition of the CD13 (MCS-2) the percentage inhibition was 68%, for CD147 CD4 ϩ and CD8 ϩ T cells respectively. (HI84) 98% and for CD148 (143-41) 96%. These results were all statistically significant (P Ͻ 0.05).
CD45RA ϩ and CD45RO ϩ T cell subsets DC induced allogeneic responses
Similar experiments were performed using fractionated CD45RA ϩ T cells or CD45RO ϩ T cells (Fig. 8) . CD87 (HD-uPATo confirm that the inhibition documented above (Figs 4-6) R15.4.1), CD98 (J1-G3B), CD147 (H84) and mAb WM-78 was not a characteristic of CD3-mediated T cell activation inhibited both CD45RA and CD45RO T cell proliferation only, we tested the mAb further in a 6 day MLR. Inhibition equally. CD13 (MCS-2) and CD148 (143-41) both inhibited was observed with CD13 (MCS-2) (20%), CD87 (Clone 109) CD45RA T cell proliferation to a greater extent than CD45RO (49%), CD98 (J1-G3B/AHN18.1) (46%), CD147 (H84) (77%), T cells. Thus, for example, CD13 (MCS-2) inhibited CD45RA CD148 (143-41) (19%), WM-78 (24%) and CD86 (50%).
T cells (42-49%, P Ͻ 0.01), but had a much smaller effect on Effect of mAb on DC-independent T cell activation CD45RO T cells (Ͻ10%). Similarly CD148 (143-41) inhibited CD45RA T cell proliferation by 53-56% (P Ͻ 0.003), whereas In view of the possibility that many of these cell surface molecules are expressed on T cells as well as on DC, and with CD45RO T cells the same mAb inhibited by 35-40%.
from inactive forms to active forms (28) and thus modulate signalling. CD13 has been implicated in antigen presentation in murine studies previously (29) in that CD13 was coordinately regulated with MHC class II expression, but no functional analysis was documented. In this study CD13 might be required to generate soluble or cell surface active peptides that are important for initiating signal transduction into the DC, or alternatively which are directly involved in the PBDC interaction with naive T cells. Likewise, CD87 showed the same inhibitory pattern as CD13. CD87 is the urokinase plasminogen activator receptor (uPAR), that is implicated in leukocyte migration and adhesion. The molecule has been co-isolated with the c-fyn tyrosine of plasminogen to plasmin, which facilitates matrix degradation and hence increases metastatic invasion (37) . This is supported by the observation that over-expression of CD87 Discussion is associated with increased tumour growth and metastasis, particularly in breast cancer (38) (39) (40) . Thus, in vivo CD87 may In this study we have explored the molecular mechanisms that are involved during activation of T cells by PBDC further, play a role in migration of DC through tissues, mediated via the same mechanism as that used by the neoplastic cell. In using an autologous culture system comprising PBDC, T cells and CD3 mAb. The system showed many of the characteristics in vitro experiments, however, it is more likely that an integrincytosteletal association required for an effective DC-T cell of physiological DC presentation: the T cell response was proportional to DC numbers and could be blocked by mAb interaction is the target site for the mAb. Our study (Fig. 1 ) demonstrated differences in expression to known accessory molecules, such as CD18, CD54 and CD86. In addition, the use of soluble CD3, rather than antibody between different CD87 epitopes, as reflected in binding by different CD87 mAb. Of seven CD87 mAb analysed, five were coated to plastic, allowed the formation of DC-T cell clusters reminiscent of those seen in antigen-specific responses positive on these PBDC. The two mAb that did not bind to PBDC recognize epitopes in the D1 and D2 domains, and a in vivo. To confirm further that the effects were not an artifact of the CD3-dependent model, the same mAb were also tested different pattern of expression with these two mAb has been reported (41) . No CD87 mAb stained T cells, consistent with in a classic MLR and a parallel inhibitory effect demonstrated.
Based upon these findings we analysed the functional previous findings, where CD87 was only seen on activated T cells (42) . All the CD87 mAb which were positive on PBDC consequences of adding a panel of mAb to a number of cellsurface molecules that we have shown recently are present recognize glycosylated forms of CD87, while the other two mAb recognize components of the amino acid backbone, on PBDC (22) . As a result, we identified an accessory role for five CD antigens (and for a potential sixth molecule, which is not exposed at the cell surface. However, these two mAb nonetheless have an inhibitory effect in the functional recognized by a mAb whose target has yet to be defined) in T cell activation by PBDC. The combination of the CD3 assay suggesting that CD87 may undergoes dynamic changes during the course of the assay. This could be due assay ('over-riding' the antigen-specific component and thus focussing on potential co-stimulatory components), the to synthesis of new CD87 in a non-glycosylated form, to deglycosylation on the surface or to change in conformation, expression of these molecules on the surface of PBDC, the observation that very similar results are seen when the mAb rendering the protein core accessible to mAb binding and hence inhibition. were pre-pulsed on to the PBDC and confirmation of the data in separate parallel work using U937 (promonocyte) cells as CD98 is a type II transmembrane glycoprotein, recently shown to co-precipitate with the β 1 integrins (43) . These accessory cells (27) all highlight the potential role of these molecules in PBDC-T cell interaction and raise the possibility studies postulated that up-regulation of integrin function requires clustering of CD98 molecules. Some CD98 mAb that this role is at the level of the PBDC.
One example of this was CD13, which is highly expressed also induce HIV gp160-mediated cell fusion to produce multinucleated giant cells (44, 45) and the molecule has been on PBDC, but not on the T cells. mAb to CD13 inhibited both standard and prepulse autologous assays, had no effect on implicated in regulation of cell survival-apoptosis (46) . A role in calcium flux into cells has been proposed, since CD98 T cell activation by PMA and ionomycin, and blocked activation of CD45RA (naive) T cell proliferation rather than CD45RO ligation causes an influx of extracellular calcium in neuronal cells (47) and galectin-3 (which is a possible CD98 ligand) (memory) T cell proliferation. CD13, or aminopeptidase N, is a zinc-dependent metalloprotease, which may remove also induces calcium flux in CD98-expressing T cells (48).
As galectin-3 is synthesized and released by accessory N-terminal residues from active peptides or convert peptides cells, it may also induce CD98-mediated autocrine effects on CD45RO T cells were used, where no consistent pattern of inhibition was found. CD148 may therefore play an important monocytes and macrophages themselves (49).
The pattern of CD98 expression on PBDC and T cells role at the level of PBDC presentation to naive, rather than memory T cells. By analogy with previous findings with CD148, shown here suggests that the molecule may exist in more than one form, possibly due to differential glycosylation or to the effects may be to decrease calcium mobilization into the PBDC, but it is also possible that in the presence of CD148 the existence of different isoforms on different cell types. Thus, on PBDC, most mAb bound with high intensity, but mAb there is unopposed tyrosine phosphorylation and hence activation of inhibitory molecules that are otherwise not readily 2E12, IPO-T10 and BU89 bound at lower levels and exhibited a biphasic distribution (Fig. 1) . This was reflected in the identified (57) . This latter hypothesis would be consistent with the observation that CD148 is also inhibitory in PBDCpattern of binding to T cells as well as to PBDC: three mAb showed strong binding (MEM108, J1-G3B/AHN-18.1 and independent assays. Finally, the other mAb with functional effects was WM-78, J3-E1B/AHN-18), two showed weak binding (CAF-7 and BU53) and the remaining mAb did not bind. A similar pattern which has not yet been cloned and allocated CD nomenclature, but was present on PBDC, and showed some expression was seen in the functional assays: mAb, J1-G3B/AHN-18.1, J3-E1B/AHN-18, BK19.9 and CAF7 all gave consistent inhibion T cells. This mAb also inhibited all assays and interestingly was the only one tested that showed selective inhibition of tion, whereas 2E12, MEM108, IPO-T10, BU53 and BU89 did not. Thus different CD98 epitopes may have different CD4 T cell proliferation rather than of CD8 T cells.
In conclusion, therefore, our study has identified six further functional roles in antigen presentation, and this could be due to their relative ability to cluster and induce a signalling molecules which appear to play a role in the antigen presentation event. In every case the mAb which recognized these cascade in the APC. Alternatively, inhibitory mAb may cause more efficient clustering of CD98 molecules and then sterically molecules were inhibitory when pre-pulsed on the APC, suggesting that their predominant effect is mediated via these hinder the integrin interaction with ligands on the T cell.
These studies are consistent with our findings with CD98 cells rather than via T cells. Only one mAb showed selective inhibition of CD4 versus CD8 T cells and two mAb preferenmAb in a U937 model system (27) and with functional studies of CD98 that showed that the molecule acts at the accessory tially inhibited CD45RA versus CD45RO cells. The latter finding is consistent with current dogma suggesting that naive cell level, both in primary T cell responses and in a xenogeneic system (51) . The inhibition (unlike that seen with CD13 and T cells have a more stringent requirement for accessory interaction than memory T cells (13, 58 ). The precise mechan-CD87 mAb) in the PMA-ionomycin-induced T cell activation is not inconsistent with this view. This may be due to an effect ism whereby each molecule exerts its effect remains to be elucidated in future studies. For example, we do not as yet on cell survival (46) or reflect the dynamic T-T cell interaction that contributes to the formation of the APC-T cell complex know whether they act in parallel or in series to known costimulatory pathways such as CD28-CD80-CD86. However, in addition to the APC-T cell component (52) . It is noteworthy that prefixation of bound CD98 before adding T cells and irrespective of the specific molecular mechanisms, the study does highlight an added level of complexity to the APC-T cell CD3 was also inhibitory. Furthermore, the previous studies of the role of CD98 in accessory cell assays used PBMC interaction, but also one which identifies several new potential targets for immunomodulation of DC in the future. Furthermore, depleted by treatment with leucine methyl ester to suggest that the effect was at the level of the monocyte: since the it is becoming increasingly clear that DC do indeed serve as the 'sentinels' responding to infection or cell injury in the local PBDC used here were derived from the same cell fraction, this implies no PBDC would have been present in the assays. micro-environment (59) , and that this may be mediated by up-regulation of the molecules on their surface that act as Therefore both these findings favour a role for CD98 at the DC level.
co-stimulators in conjunction with the antigen-specific TCRmediated events and control migration to lymph nodes; and CD147, neurothelin, was described originally on endothelial cells at the blood-brain barrier (53) and may play a role in that the same molecules may select not only for antigen presentation per se but also for determining outcome, as nutrient transport. The distribution of CD147 is regulated by cell-cell interactions and co-localizes with F-actin, exhibiting reflected by 'tolerance' versus 'responsiveness'. The findings reported here suggest that these six potential novel coa polarized distribution on the cell surface (54) . Neurothelin knockout mice showed little or no difference in blood-brain stimulatory molecules all need to be considered as components in this critical stage of response induction. barrier function, although paradoxically lymphocytes from the knockout mice produced a greater proliferative response in an MLR, than those of wild-type littermates (55) . In our analysis Acknowledgements CD147 was expressed on both PBDC and T cells, and CD147
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